MK-6194 in non-segmental vitiligo: a Treg-selective IL-2 mutein that matched placebo

What was tried

MK-6194 is an engineered interleukin-2 mutein designed to preferentially engage the high-affinity IL-2 receptor and selectively expand regulatory T cells, developed as a biologic without a small-molecule ChEMBL entry (ImmunoHorizons, 2025). Merck acquired the asset through its 1.9 billion dollar purchase of Pandion Therapeutics in 2021 (FierceBiotech, 2025). NCT06113328 was a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study run by Merck Sharp and Dohme to evaluate the efficacy and safety of MK-6194 in adults with non-segmental vitiligo (ClinicalTrials.gov NCT06113328). Participants received MK-6194 3 mg every two weeks, 3 mg every four weeks, or placebo under quadruple masking, with a primary endpoint of percent change from baseline in the Facial Vitiligo Area Scoring Index at Week 24. Actual enrollment reached 169, and primary completion was March 20, 2025. The registry lists the stop reason as Business Reasons, and Merck removed MK-6194 from its pipeline after concluding the asset lacked clinical benefit over placebo (FierceBiotech, 2025).

The biological hypothesis

Non-segmental vitiligo is an autoimmune disease in which autoreactive CD8 T cells destroy melanocytes, driven by an interferon-gamma signature and the CXCL9 and CXCL10 to CXCR3 axis that maintains cytotoxic T cells in skin (European Journal of Immunology, 2024). CXCL10 was critical for depigmentation in a mouse model of vitiligo (Science Translational Medicine, 2014). Regulatory T cells restrain this response, and low-dose IL-2 approaches expand Tregs and have shown activity across autoimmune settings (International Reviews of Immunology, 2024). Human IL-2 immunotherapy expands defined Treg subsets (Immunity, 2024). MK-6194 was built to sharpen that selectivity, expanding Tregs while sparing effector and NK cells, and its early-phase data confirmed dose-dependent Treg expansion (ImmunoHorizons, 2025). The target also has genetic support in this indication. Open Targets records an IL2RA to vitiligo association of 0.3854, with a genetic association datatype score of 0.617 that reflects GWAS evidence, alongside literature support of 0.342 (Open Targets Platform, 2025). IL2RA is an antibody-tractable, approved-drug-class target, so restoring Treg control in a genetically supported autoimmune disease was a reasonable hypothesis.

What actually happened

The trial reached its primary readout, and the effect on skin was small and indistinguishable from placebo. In posted results, the least-squares mean percent change from baseline in Facial VASI at Week 24 was -4.55 percent for the every-two-weeks arm, -12.13 percent for the every-four-weeks arm, and -4.01 percent for placebo, with wide 95 percent confidence intervals that overlapped heavily and, for both active arms, crossed zero (ClinicalTrials.gov NCT06113328, posted results). Total VASI followed the same pattern, at -1.69, -9.08, and 0.78 percent respectively. The every-two-weeks arm sat on top of placebo, and the every-four-weeks confidence interval reached to 0.03 percent, so no arm separated convincingly. MK-6194 has no OpenFDA FAERS reports, consistent with an investigational biologic (OpenFDA FAERS, retrieved 2026-07-11). Merck recorded the stop as a business decision in the registry, while the public account attributed the discontinuation to a lack of clinical benefit over placebo (FierceBiotech, 2025). The gap between a clean pharmacodynamic effect on Tregs and an absent effect on repigmentation is the core of the failure.

Failure mechanism, best guess

The proximate archetype was an efficacy failure, and the mechanistic tension was a translational mismatch between Treg expansion and melanocyte recovery. Expanding regulatory T cells can dampen ongoing autoimmune attack, but repigmentation in vitiligo requires two further steps that Treg control alone may not deliver. It requires durable suppression of the resident memory CD8 T cells that garrison lesional skin, and it requires active melanocyte regeneration from follicular reservoirs. A systemic Treg-biasing agent may not reach skin-resident memory T cells, and it does nothing to stimulate melanocyte outgrowth, so a real immunologic effect can fail to translate into visible color return over 24 weeks. Vitiligo trials also carry a slow, high-variance endpoint, and the wide confidence intervals here are consistent with an under-powered separation. The registry reason of Business Reasons understates the mechanistic read, which the posted Facial VASI data make plain.

How to prevent this next time

Two quantitative tools would have improved the odds of an interpretable result. First, a Bayesian predictive-probability design with an interim futility rule would have quantified the chance of a positive Week 24 readout given early data, using:

PP(success)=∫θ​P(final success∣θ,interim data)⋅π(θ∣interim data)dθ

A prior anchored on the known placebo drift and slow repigmentation kinetics of vitiligo would have set a realistic bar, and an interim predictive probability below a preset threshold would have stopped the every-two-weeks arm early rather than carrying two arms to a wide, inconclusive endpoint. Second, biomarker enrichment paired with an explicit power calculation on a responder endpoint would have sharpened the design. Enriching for recent-onset or actively spreading disease with a high interferon-gamma and CXCL10 signature, and powering on Facial VASI 75 responders rather than mean change, would reduce the variance that swamped this readout. Historical base rates reinforce the caution, since dermatology autoimmune programs face large placebo responses and only a minority of Phase 2 assets advance (Wong, Siah, and Lo, 2019). The single highest leverage change would have been ...

What this means for similar programs

Treg-directed IL-2 muteins remain in development for autoimmune disease, with rezpegaldesleukin and efavaleukin alfa among the class, and the lesson from MK-6194 is that pharmacodynamic Treg expansion is necessary but not sufficient for a tissue-remodeling endpoint. In vitiligo, the approved topical JAK inhibitor ruxolitinib cream sets a repigmentation benchmark a systemic immunomodulator must clear, and programs should confirm effects on skin-resident memory T cells and melanocyte recovery, not only circulating Tregs. Genetic support for IL2RA in vitiligo did not rescue the program, a reminder that a validated target can still fail on the wrong pharmacology or endpoint.

Open questions

Did MK-6194 expand Tregs in lesional skin, or only in blood, over the 24 weeks. Would a longer treatment period or a responder-based endpoint have revealed a delayed signal in the every-four-weeks arm. Does combining Treg expansion with resident memory T cell depletion or a repigmentation stimulus change the outcome. Will other Treg-selective IL-2 agents show the same disconnect between pharmacodynamics and repigmentation in vitiligo.

Sources

1. • ClinicalTrials.gov, NCT06113328, terminated status, whyStopped Business Reasons, enrollment 169, Phase 2a design, Facial VASI and Total VASI posted results, primary completion 2025-03-20: https://clinicaltrials.gov/study/NCT06113328 - FierceBiotech, Merck axes midstage asset from 1.9B Pandion buyout due to lack of clinical benefit, 2025: https://www.fiercebiotech.com/biotech/merck-axes-midstage-asset-19b-pandion-buyout-due-lack-clinical-benefit - Open Targets Platform, IL2RA (ENSG00000134460) to vitiligo (MONDO_0008661) association 0.3854, genetic association datatype 0.617: https://platform.opentargets.org/target/ENSG00000134460 - Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells. ImmunoHorizons.

2. - The IFN-gamma-CXCL9/CXCL10-CXCR3 axis in vitiligo. European Journal of Immunology.

3. - CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Science Translational Medicine.

4. - Low-dose IL-2 therapy in autoimmune diseases: an update review. International Reviews of Immunology.

5. - Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics. Immunity.

6. - Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273-286.